BIAL enters the US and acquires “promising” Parkinson’s disease programmes

BIAL enters the US and acquires “promising” Parkinson’s disease programmes
Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease. BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a ... read more
Source: Parkinson’s Life EUPublished on 2020-10-08By admin